JAK Inhibitor Market to Register Immense Growth by 2034, Predicts DelveInsight | Key Companies - Eli Lilly and Company, Incyte Corporation, Dompé Farmaceutici S.p.A, Sanofi, Celgene, AstraZeneca, Karyopharm Therapeutics
May 15, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, May 15, 2024 (GLOBE NEWSWIRE) -- JAK Inhibitor Market to Register Immense Growth by 2034, Predicts DelveInsight | Key Companies - Eli Lilly and Company, Incyte Corporation, Dompé...
Janus Kinase (JAK) Inhibitor Market Forecast 2024-2034: Analyzes Trends Likely to Shape Future Opportunities
March 14, 2024 04:30 ET
|
Research and Markets
Dublin, March 14, 2024 (GLOBE NEWSWIRE) -- The "Janus Kinase (JAK) Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ...
Charting New Paths: Non-TNF's Evolving in Rheumatoid Arthritis Market
February 23, 2024 13:50 ET
|
Spherix Global Insights
EXTON, PA, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Amidst the array of advanced treatment avenues available for rheumatoid arthritis (RA), ranging from legacy TNF inhibitors and their newer biosimilar...
When it Comes to Treating Ulcerative Colitis, US Gastroenterologists May be Betting it All on JAK…
November 30, 2023 10:59 ET
|
Spherix Global Insights
Exton, Pennsylvania, Nov. 30, 2023 (GLOBE NEWSWIRE) -- With the Ulcerative Colitis (UC) market set to heat up in the coming months, the JAK class seems poised to become a dominant treatment,...
XELJANZ for Ulcerative Colitis (UC) Pipeline Report 2023: Drug Market Insights and Forecasts, 2019-2032 - Focus on 7 Major Markets
November 23, 2023 11:23 ET
|
Research and Markets
Dublin, Nov. 23, 2023 (GLOBE NEWSWIRE) -- The "XELJANZ Market Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering. "XELJANZ Market Drug...
Eli Lilly's Olumiant and Pfizer's Litfulo Strengthen Alopecia Areata Arsenal, Yet Resounding Opportunity for JAK Expansion and New Assets in Development Remain
November 15, 2023 11:22 ET
|
Spherix Global Insights
Exton, Pennsylvania, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Spherix Global Insights has been monitoring the alopecia areata (AA) market for the past four years and has found that the entry of JAK...
JAK Inhibitors Market Surges as Autoimmune Diseases Demand Cutting-Edge Solutions, 2032F: Revenues for Ruxolitinib, Tofacitinib, Oclacitinib, Baricitinib, Peficitinib, and Other Inhibitor Types
November 01, 2023 08:18 ET
|
Research and Markets
Dublin, Nov. 01, 2023 (GLOBE NEWSWIRE) -- The "Global Janus Kinase (JAK) Inhibitors Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The global Janus Kinase (JAK)...
Global Tofacitinib Market Research Report 2023
October 17, 2023 05:18 ET
|
Research and Markets
Dublin, Oct. 17, 2023 (GLOBE NEWSWIRE) -- The "Tofacitinib Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.The global tofacitinib market is expected to grow...
Pfizer’s Litfulo Poised to Follow Similar Trajectory as Eli Lilly/Incyte’s Olumiant for the Treatment of Severe Alopecia Areata
July 11, 2023 09:58 ET
|
Spherix Global Insights
Exton, Pennsylvania, July 11, 2023 (GLOBE NEWSWIRE) -- In June 2022, Eli Lilly and Incyte’s Olumiant became the first and only approved advanced systemic treatment for adults with severe alopecia...
JAK Inhibitors Competitive Landscape 2023: Comprehensive Insights on 40+ Companies and 45+ Drug Profiles
May 08, 2023 06:38 ET
|
Research and Markets
Dublin, May 08, 2023 (GLOBE NEWSWIRE) -- The "JAK inhibitors - Competitive Landscape, 2023" report has been added to ResearchAndMarkets.com's offering.This "JAK inhibitors - Competitive landscape,...